As the industry continues to adopt a patient-centric approach, the use of real-world data is becoming increasingly essential in informing drug development and regulatory decision-making. Read about the FDA's guidance on Patient-Focused Drug Development (PFDD) to enhance your product development and regulatory decision-making👇 https://hubs.li/Q02Fw4sQ0 #PFDD #DrugDevelopment #patient
About us
Veristat is the science-first full-service drug and biologic CRO and consultancy that integrates strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies. At Veristat, we collaborate with clients to support the rapid delivery of life-changing therapies, helping them make sound decisions amidst uncertainties. Our scientific experts design and conduct the global activities required for any clinical, regulatory, or commercialization program comprehensively and efficiently. With our focus on novel drug development and nearly 30 years of experience, our versatile approach and bold scientific thinking make the impossible possible. Depend on our game-changing expertise and reliable execution for fast results and positive impact to support your biologics and drugs to treat rare cancers, CNS/Neurological disorders, Endocrine/metabolic disorders, and infectious diseases. We are…Bold. Scientific. Versatile. Veristat. - Veristat has recently been made aware that unknown third parties that have no connection to Veristat are generating fake Veristat job postings, interviews, and even fake employment offers via emails, websites, and various social media platforms, seemingly for the purpose of fraudulently obtaining personal information from legitimate job candidates. All legitimate correspondence from Veristat will originate from our applicant tracking system (Jobvite) or an @veristat.com email address. If you have received outreach from someone claiming to be a member of our team please search our official LinkedIn company page (https://www.linkedin.com/company/veristat-llc), where all members of our authorized recruiting team can be identified, or contact us directly at talentacquisition@veristat.com. Be vigilant.
- Website
-
http://www.veristat.com
External link for Veristat
- Industry
- Research Services
- Company size
- 501-1,000 employees
- Headquarters
- Southborough, Massachusetts
- Type
- Privately Held
- Specialties
- Strategic Consulting, Safety Management, Data Management, Biostatistics, Statistical Programming, Project Management, Medical Writing, Regulatory Submissions, Adaptive Clinical Trial Design, Site Monitoring, Regulatory Consulting, Clinical Trial Patient Recruitment, Clinical Trial Data Standardization, Clinicl Trial Design, Clinical Trial Management, US Regulatory Agent, Pharmacovigilance, Marketing Applications Support, IND Support, Regulatory Publishing, Biologic, Gene Therapy, Full-service CRO, and Oncology Clinical Trials
Locations
Employees at Veristat
Updates
-
The EMA published information material for accelerating the clinical trials in the EU initiative (ACT EU). This includes: 📍Map of national projects supporting non-commercial sponsors at the national level 📍Webpage with detailed information on the stakeholders and groups within the European Medicines Regulatory Network (EMRN) Read more > https://hubs.li/Q02FwbVy0 #clinicalresearch #clinicaltrials #CTIS
-
Hear from our CCO, Rachel Page, as she joins Sterling Bay's webinar as a panelist to discuss 'A Triangle Perspective on AI, ML, & the Future of Drug Development.' The panel will address how AI/ML developments are revolutionizing the global biopharmaceutical industry. Register today 👇 https://hubs.li/Q02F-yM-0 #globalbiopharmaceutical #DrugDevelopment
-
The FDA issued draft guidance on essential drug delivery outputs for devices intended to deliver drugs and biological products. The guidance: 👉 Targets combination products 👉 Aims to streamline device development 👉 Offers recommendations on design outputs 👉 Informs drug delivery performance Stakeholders may submit comments on the draft by 30 September 2024 > https://hubs.li/Q02FwgPl0 #IVDs #medtech #regulatoryaffairs
EDDO for Devices Intended to Deliver Drugs and Biological Products
fda.gov
-
Facing staffing reductions in Biopharma? Discover how strategic FSP resourcing can help Biotech firms navigate talent shortages and achieve clinical trial success. Read now 👉 https://hubs.li/Q02F-yMb0 #biopharma #biotech #clinicaltrials
FSP/Resourcing: Meeting the Moment with Expert Resources
veristat.com
-
Innovative Health Initiative (IHI) launched a call for proposals on dealing with pressing challenges in health research and innovation. The funding round covers several topics: ➡ Combating cardiovascular disease in cities ➡ Using big data to make progress on osteoarthritis ➡ Regulatory sandboxes to support breakthrough innovation ➡ Understanding how best to capture patient-centered information Deadline: 10 October 2024 https://hubs.li/Q02FyMWx0 #pharma #lifesciences
Cardiovascular disease and arthritis among topics of new IHI funding round
ihi.europa.eu
-
Lacking internal resources to advance your clinical trial? At Veristat, we can support your success across the entire drug development journey with our scientific thinking and flexible approach. Learn more ⬇️ https://hubs.li/Q02Fwb-30 #biopharma #biotech #clinicaltrials
-
The European Commission published a revised version of Medical Device Coordination Group (MDCG) guidance 2021-5 on standardization for medical devices. Revisions include: 📌 Additions on the references to EN ISO 15189 and ISO 14155:2011 📌 Updates on the Harmonized Standards 📌 A new section handling common specifications Read more > https://hubs.li/Q02FwdFD0 #MDR #IVDR #MedicalDevices
Guidance on Standardization for Medical Devices
health.ec.europa.eu
-
Accelerate your cell or gene therapies to market with tailored clinical and regulatory strategies and expert insights. 📽️ Discover how we can help you with your unique cell and gene clinical trials and consulting projects. Watch now > https://hubs.li/Q02FwdFz0 #VeristatYoutube #CellandGene
-
The European Commission published the Science, Research and Innovation Performance Report. The report highlights: ➡ EU research & innovation ecosystem (R&I) remains underutilized ➡ Divide in R&I for activities/support ➡ Gap with the rest of the world raising private investments The report offers several recommendations: ➡ Improve the sector of research universities ➡ Allocate a fraction of R&I funds to government research labs and introduce accountability reforms ➡ Create an Advanced Research Projects Agency for Health (ARPA) modeled after the US ARPA-H Read more > https://hubs.li/Q02Fw8Qv0 #ResearchAndInnovation #pharmaceutical
Science, Research and Innovation Performance Report.
ec.europa.eu